Minor Cannabinoids Beyond THC and CBD: CBG, CBN, CBC, and THCV - Molecular Structure, Receptor Affinity, and Why They Matter

Most people know THC and CBD. The plant makes over 100 other cannabinoids in small amounts. Four of them are commercially available now and have distinct pharmacology that is often misunderstood.

CBG - Cannabigerol: The Stem Cell Cannabinoid

Molecular formula C21H32O2, molecular weight 316.48 g/mol. CBG is called the mother cannabinoid because CBGA, its acidic precursor, is the biosynthetic branch point. Enzymes convert CBGA into THCA, CBDA, and CBCA. If a plant is high in THC, it has low CBG because CBGA was converted.

Receptor affinities: CB1 Ki 440-1045 nM weak agonist, CB2 Ki 150-1225 nM partial agonist. Compared to THC Ki at CB1 ∼10 nM, CBG is very weak at CB1, which is why it is non-intoxicating. Its more relevant targets are TRPM8 at 160 nM antagonist which affects cooling and pain sensation, alpha-2-adrenergic receptor at 0.2-73 nM agonist linked to sedation and blood pressure regulation, and 5-HT1A at ∼52 nM antagonist linked to anxiolytic effects.

Key effects in preclinical studies: anti-inflammatory via PPAR-gamma, antibacterial including MRSA, neuroprotective in Huntington models, appetite stimulation, potential intraocular pressure reduction studied for glaucoma. Non-psychoactive. Low affinity for CB1/CB2 compared to THC is a feature for daytime use.

CBN - Cannabinol: The Degradation Product

Molecular formula C21H26O2, molecular weight 310.44 g/mol. CBN is not made by the plant directly. It is an oxidative degradation product of THC. When THC is exposed to oxygen, heat, and UV over time, it converts to CBN. Old cannabis tests higher in CBN.

Receptor affinities: CB1 ∼200-500 nM low-affinity partial agonist, CB2 ∼120-300 nM partial agonist, TRPA1 ∼180 nM agonist which is involved in pain and inflammatory sensory signaling.

Key effects: Commonly marketed as sedative and sleep aid. Studies show mild psychoactivity at high doses, about 10% of THC potency. Analgesic and anti-inflammatory in animal models, antibacterial, and potential appetite stimulant. Non-intoxicating at typical doses under 5mg but can become mildly intoxicating above 20-30mg in sensitive individuals. This dose dependence matters for edibles formulation.

CBC - Cannabichromene: The TRPA1 Specialist

Molecular formula C21H30O2, molecular weight 314.46 g/mol. Third most common cannabinoid in some chemovars.

Receptor affinities: CB1 ∼700 nM very low affinity, CB2 ∼250 nM low affinity agonist. Minimal direct CB1/CB2 activity. Most potent activity is at TRPA1 ∼90 nM potent agonist. TRPA1 is a pain, itch, and cold sensor channel in peripheral nerves. Also weak TRPV3/4 agonist at 1000-5000 nM.

Key effects: Non-psychoactive. Strongest research is for anti-inflammatory and analgesic via TRP channels, not CB receptors. Antidepressant potential in animal forced swim tests, possibly via TRPA1 and anandamide reuptake inhibition. Neuroprotective and antimicrobial. Often overlooked because it does not bind CB1 strongly, but TRP channel modulation is how many non-cannabinoid plants like mustard and garlic work.

THCV - Tetrahydrocannabivarin: The Dose-Dependent Switch

Molecular formula C19H26O2, molecular weight 286.41 g/mol. Propyl homolog of THC. Same core but with 3-carbon side chain instead of 5-carbon.

Receptor affinities and biphasic pharmacology: CB1 antagonist at low dose, agonist at high dose. This is critical. At low doses under 5-10mg, THCV blocks CB1, can suppress appetite and reduce THC intoxication. At high doses over 20-30mg, it becomes a CB1 partial agonist and is intoxicating with shorter, clearer effects than THC. CB2 Ki 38-280 nM partial agonist. 5-HT1A agonist for mood and anxiety. TRPV1 ∼1.5 uM agonist.

Key effects: Appetite suppression most potent at low doses, improved glucose tolerance and insulin sensitivity studied for weight management and diabetes, anticonvulsant and anti-epileptic potential, reduces anxiety at low doses. Inhibits FAAH and MGL enzymes which raises your own endocannabinoids anandamide and 2-AG.

Dose matters more with THCV than any other cannabinoid. Low dose = antagonist and appetite suppressant. High dose = agonist and psychoactive.

Summary Comparison for Formulation

CBG: Weak CB1/CB2, strong alpha-2 adrenergic and 5-HT1A activity. For neuroprotection, antibacterial, inflammation, glaucoma. Daytime, non-sedating.

CBN: Low-affinity CB1/CB2 partial agonist, TRPA1 agonist. For sedation, sleep, pain relief, antibacterial. Evening use.

CBC: Very low CB1/CB2, potent TRPA1 agonist. For anti-inflammatory, antidepressant potential, antimicrobial, bone growth research.

THCV: CB1 antagonist low dose, partial agonist high dose. For appetite suppression and weight management at low dose, anti-seizure, metabolic health.

All Ki values are from in vitro binding studies. In vivo effects depend on metabolism, bioavailability, and individual CYP450 genetics. All effects are preclinical or research-based, not medical advice. For adults 21+ where legal.